Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2019, Vol. 41 ›› Issue (5): 673-677.doi: 10.38/j.issn.1000-503X.10940

• Original Articles • Previous Articles     Next Articles

Discordance of Estrogen Receptor,Progesterone Receptor,Cerb-B2,Ki-67 Index and P53 Expressions between Primary and Recurrent or Metastatic Sites in Breast Cancer Patients

PENG Li1,ZHAO Jialin1,ZHAO Dachun2,ZHANG Yanna1,MAO Feng1,SUN Qiang1()   

  1. 1 Department of Breast Surgery
    2 Department of Pathology,PUMC Hospital,CAMS amd PUMC,Beijing 100730,China
  • Received:2018-10-18 Online:2019-10-30 Published:2019-11-08
  • Contact: Qiang SUN E-mail:sunqiangpumc@sina.com

Abstract:

Objective To approach the discordance of estrogen receptor(ER),progesterone receptor(PR),Cerb-B2,Ki-67 index and P53 expressions between primary and regional or distant recurrent lesions in recurrent or metastatic breast cancer patients.Methods Clinical and pathological data of 56 recurrent or metastatic breast cancer patients who were treated in Peking Union Medical College Hospital from January 2001 to February 2015 were retrospectively analyzed.The changes in the expressions of ER,PR,Cerb-B2,Ki-67 index,and P53 status were analyzed.Results The hormone receptor positive rate between primary tumor and recurrent or metastatic sites decreased from 60.7% to 57.1% for ER and from 55.4% to 44.6% for PR,respectively.Changes in hormone receptor status were seen at the rate of 12.5%(7/56)and 16.1%(9/56)for ER and PR,respectively.Cerb-B2 receptor positive rate increased from 19.1% to 29.5% and the discordance rate was 9.1%(4/44).The discordance rate of Ki-67 index was 24.5%(12/49).The P53 receptor positive rate increased from 37.5% to 55.6% and the discordance rate was 13.3%(6/45).Conclusion Although the relevant rules of above changes are still controversial,these findings still have great clinical significance for making effective treatment decisions of recurrent or metastatic breast cancer.

Key words: primary breast cancer, recurrent or metastatic lesions, estrogen receptor, progesterone receptor, Cerb-B2 receptor

CLC Number: